Phase Ib study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer-Reference-Cited by-同舟云学术

Phase Ib study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer

Published:2020-05 Issue:2 Volume:157 Page:379-385
ISSN:0090-8258
Container-title:Gynecologic Oncology
language:en
Short-container-title:Gynecologic Oncology

Author:

O'Malley David M.,Matulonis Ursula A.,Birrer Michael J.,Castro Cesar M.,Gilbert Lucy^ORCID,Vergote Ignace,Martin Lainie P.,Mantia-Smaldone Gina M.,Martin Antonio González,Bratos Raquel,Penson Richard T.,Malek Karim,Moore Kathleen N.

Funder

ImmunoGen, Inc.

Publisher

Elsevier BV

Subject

Obstetrics and Gynaecology,Oncology

Reference39 articles.

1. Management of newly diagnosed or recurrent ovarian cancer;Matulonis;Clin. Adv. Hematol. Oncol.,2018

2. Treatment of recurrent ovarian cancer;Pignata;Ann. Oncol.,2017

3. Front-line therapy of advanced epithelial ovarian cancer: standard treatment;Marth;Ann. Oncol.,2017

4. “Platinum resistant” ovarian cancer: what is it, who to treat and how to measure benefit?;Davis;Gynecol. Oncol.,2014

5. Bevacizumab in ovarian cancer: a critical review of phase III studies;Rossi;Oncotarget,2017

Cited by 95 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Near fatal case of mirvetuximab soravtansine-gynx induced interstitial lung disease and a review of the primary literature;Gynecologic Oncology Reports;2024-10

2. Maintenance with mirvetuximab soravtansine plus bevacizumab vs bevacizumab in FRα-high platinum-sensitive ovarian cancer;Future Oncology;2024-07-31

3. Preclinical studies of RA475, a guanidine-substituted spirocyclic candidate RPN13/ADRM1 inhibitor for treatment of ovarian cancer;PLOS ONE;2024-07-11

4. New hopes and promises in the treatment of ovarian cancer focusing on targeted treatment—a narrative review;Frontiers in Pharmacology;2024-06-14

5. Phase 1b study of mirvetuximab soravtansine, a folate receptor alpha (FRα)–targeting antibody-drug conjugate, in combination with carboplatin and bevacizumab in patients with platinum-sensitive ovarian cancer;Gynecologic Oncology;2024-06